<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83968">
  <stage>Registered</stage>
  <submitdate>26/05/2009</submitdate>
  <approvaldate>7/07/2014</approvaldate>
  <actrnumber>ACTRN12614000716662</actrnumber>
  <trial_identification>
    <studytitle>Formation of bilirubin photoisomers in optimalized phototherapy of neonatal jaundice.</studytitle>
    <scientifictitle>Early Isomerization of Bilirubin in Optimized phototherapy of neonatal jaundice</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym>Nil</trialacronym>
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neonatal jaundice</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Childbirth and postnatal care</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Complications of newborn</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intensified phototherapy with  single  fluorescent unit (one Bilicompact  light)  vs Double fluorescent unit (double bilicompact. light) vs phototherapy with Photodiodes (Neoblue).
The neoBLUE unit emits blue LED light in the 450-470 nm with peak at 468 nm spectrum. This range corresponds to the bilirubin peak absorption wavelength of 458 nm.
BiliCompact contains ten 9W,12.7-cm length fluorescent bulbs (BAM/PL9/52, Ralutec 9W/71 G 23). These bulbs have broad Gaussian emission spectra roughly from 400 -525 nm with a peak at 450 nm and intense mercury emission lines at 405, 436, and 546 nm
Arm 1: Single phototherapy  provided by  one unit neoBLUE `Trademark`
Arm 2: Single phototherapy with single unit BiliCompact.`Trademark`. Arm 3: Double phototherapy was administered by two units BiliCompact`Trademark`.
 We will take blood sample to analyse bilirubin photoisomer  right befor starting phototherapy, after 30 min.60 min, 120 min Duration of phototherapy depends on the patient's response to phototherapy and how quickly falls serum total bilirbin. For this study, all children receive phototherapy at least 2-4 hours, because we are interested to see how quickly formed fotoisomerer after 15 min, 30min, 60 min, 120 min and 240 min.and 240 min. during phototherapy.</interventions>
    <comparator>In our study we compare the effect of these types of phototherapy. We ciompared singel flourescent vs. single LED photodiodes vs double flourescent phototherapy.
By conventional phototherapy means  the standard phototherapy which uses usually in the department, here is flourescent phototherapy. We would use intensive phototherapy to babies which needs phototherapy according to national Norwegean guidelines.
Phototherapy will provide by flourescent units 
(1 or 2 lamps Bilicompact) and with  single photodiodes (neoBLUE) unit at distance of 20 cm.The bed  of patient will be covered inside with white linen and by hanging  white linen  around the unit .
.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Formation of bilirubin isomers.
Stereoisomers  of bilirubin formed during phototherapy.
We will measure these photoisomers  by HPLC method. HPLC ( High-performance Liquid Chromaatography) for analyse of photoisomer.W will measure photoisomers who formed at 0 min, 15 min, 30 min., 60 min, 120 min &amp; 240 min.
HPLC method: Bilirubin isomer were analyzed on a Dionex ultimate 3000 system , including a multiple wavelength detector ( Dionex, Sunnyvale, CA). The collumn used for HPLC was  Kinetex core-shell 2,6 um  C-18 ( 15 x0,46 cm).</outcome>
      <timepoint>From onset phototherapy until maximum 4 hours as function of time.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of phototherapy.
Measuring the time of phototherapy.</outcome>
      <timepoint>0, 15, 30, 60,  120, 240 min.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Neonates with  jaundice.

( Only neonate with jaundiice  with BW &gt; 1000 g)
</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Hours</inclusiveminagetype>
    <inclusivemaxage>2</inclusivemaxage>
    <inclusivemaxagetype>Weeks</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Premature infants &lt; 1000 g body weight</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Accepted by the local ethics committee. Informed consent from the parents. Closed envelopes with infomation of which treatment to provide.(random sorted)</concealment>
    <sequence>Enrolled infants were randomized by drawing of sealed envelopes, to be treated with: 
1) single fluorescent phototherapy (BiliCompact Infant or 
2) double fluorescent phototherapy (BiliCompact), or 
3) single unit photodiodes </sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>15/05/2009</anticipatedstartdate>
    <actualstartdate>28/05/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>18/01/2012</actualenddate>
    <samplesize>42</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Norway</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Faculty of Medicine, University of Oslo </primarysponsorname>
    <primarysponsoraddress>Faculty of Medicine
PO BOX 1078 Blindern, 0316 Oslo, Norway

</primarysponsoraddress>
    <primarysponsorcountry>Norway</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Unfunded</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Bilirubin photoisomers theoretically should be less able to cross the blood-brain barrier.Therfore it is of interest to study early bilirubin izomerization during phototherapy.</summary>
    <trialwebsite />
    <publication>Mrehil k, Nakstad B, McDonaugh A.F, Hansen TWR. Early Isomerization of bilirubin in intensive phototherapy of neonatal jaundice. Ped Acad Sos 2842.403
SPAE-2009-0332 - Reversibility of acute intermediate phase bilirubin encephalopathy
Hansen TWR et al. Acta Ped (in press)</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Regional Comitee for medical research ethics, South East Norway</ethicname>
      <ethicaddress>Postboks 1130 Blindern
0318 Oslo</ethicaddress>
      <ethicapprovaldate>14/01/2009</ethicapprovaldate>
      <hrec>S-06385a</hrec>
      <ethicsubmitdate>3/01/2009</ethicsubmitdate>
      <ethiccountry>Norway</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Hansen Thor Willy Ruud.</name>
      <address>Women and Infants Division, 
Oslo University Hospital-Rikshospitalet
Sognsvannsveien 20
0027-Oslo</address>
      <phone>+4723074573</phone>
      <fax />
      <email>t.w.r.hansen@medisin.uio.no</email>
      <country>Norway</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Khalaf Mreihil</name>
      <address>Department of Pediatrics and Adolescent medicine, 
Akerhus University Hospital,
Sykehusveien
1472-Lorenskog
 Norway</address>
      <phone>+47 91 33 76 07</phone>
      <fax />
      <email>khalaf.mreihil@medisin.uio.no;khalaf.mreihil@ahus.no;khalafm@broadpark.no</email>
      <country>Norway</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Khalaf Mreihil</name>
      <address>Department of Pediatrics and Adolescent medicine, 
Akerhus University Hospital,
Sykehusveien
1472-Lorenskog
 Norway</address>
      <phone>+47 67 96 45 02</phone>
      <fax />
      <email>khalaf.mreihil@medisin.uio.no ; khalaf.mreihil@ahus.no ; khalafm@broadpark.no</email>
      <country>Norway</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Khalaf Mreihil</name>
      <address>Department of Pediatrics and Adolescent medicine, 
Akerhus University Hospital,
Sykehusveien
1472-Lorenskog
 Norway</address>
      <phone>+4791337607</phone>
      <fax />
      <email>khalaf.mreihil@medisin.uio.no</email>
      <country>Norway</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>